Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalisations and a substantial number of outpatient visits ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...